Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

11-01-2024 | Review

COVID-19-related health utility values and changes in COVID-19 patients and the general population: a scoping review

Auteurs: Zhuxin Mao, Xiao Li, Mark Jit, Philippe Beutels

Gepubliceerd in: Quality of Life Research | Uitgave 6/2024

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To summarise the diverse literature reporting the impact of COVID-19 on health utility in COVID-19 patients as well as in general populations being affected by COVID-19 control policies.

Methods

A literature search up to April 2023 was conducted to identify papers reporting health utility in COVID-19 patients or in COVID-19-affected general populations. We present a narrative synthesis of the health utility values/losses of the retained studies to show the mean health utility values/losses with 95% confidence intervals. Mean utility values/losses for categories defined by medical attendance and data collection time were calculated using random-effects models.

Results

In total, 98 studies—68 studies on COVID-19 patients and 30 studies on general populations—were retained for detailed review. Mean (95% CI) health utility values were 0.83 (0.81, 0.86), 0.78 (0.73, 0.83), 0.82 (0.78, 0.86) and 0.71 (0.65, 0.78) for general populations, non-hospitalised, hospitalised and ICU patients, respectively, irrespective of the data collection time. Mean utility losses in patients and general populations ranged from 0.03 to 0.34 and from 0.02 to 0.18, respectively.

Conclusions

This scoping review provides a summary of the health utility impact of COVID-19 and COVID-19 control policies. COVID-19-affected populations were reported to have poor health utility, while a high degree of heterogeneity was observed across studies. Population- and/or country-specific health utility is recommended for use in future economic evaluation on COVID-19-related interventions.
volgende artikel Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
2.
3.
Alzueta, E., Perrin, P., Baker, F. C., Caffarra, S., Ramos-Usuga, D., Yuksel, D., & Arango-Lasprilla, J. C. (2021). How the COVID-19 pandemic has changed our lives: A study of psychological correlates across 59 countries. Journal of Clinical Psychology, 77(3), 556–570.PubMedCrossRef
4.
Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M., Rasoulpoor, S., & Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Globalization and Health, 16(1), 57.PubMedPubMedCentralCrossRef
5.
Rezapour, A., Souresrafil, A., Peighambari, M. M., Heidarali, M., & Tashakori-Miyanroudi, M. (2021). Economic evaluation of programs against COVID-19: A systematic review. International Journal of Surgery, 85, 10–18.PubMedCrossRef
6.
Sharma, D., Aggarwal, A. K., Downey, L. E., & Prinja, S. (2021). National healthcare economic evaluation guidelines: A cross-country comparison. PharmacoEconomics-Open, 5(3), 349–364.PubMedPubMedCentralCrossRef
7.
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford University Press.
8.
Painter, C., Isaranuwatchai, W., Prawjaeng, J., Wee, H. L., Chua, B. W. B., Huynh, V. A., Lou, J., Goh, F. T., Luangasanatip, N., & Pan-Ngum, W. (2021). Avoiding trouble ahead: Lessons learned and suggestions for economic evaluations of COVID-19 vaccines. Applied Health Economics and Health Policy, 19(4), 463–472.PubMedPubMedCentralCrossRef
9.
Bagepally, B. S., Haridoss, M., Natarajan, M., Jeyashree, K., & Ponnaiah, M. (2021). Cost-effectiveness of surgical mask, N-95 respirator, hand-hygiene and surgical mask with hand hygiene in the prevention of COVID-19: Cost effectiveness analysis from Indian context. Clinical Epidemiology and Global Health, 10, 100702.PubMedPubMedCentralCrossRef
10.
Carta, A., & Conversano, C. (2021). Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients-a hypothetical study. BMC Health Services Research, 21, 986.PubMedPubMedCentralCrossRef
11.
Jiang, Y., Cai, D., Chen, D., Jiang, S., Si, L., & Wu, J. (2021). Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. British Journal of Clinical Pharmacology, 87(11), 4386–4396.PubMedCrossRef
12.
Sheinson, D., Dang, J., Shah, A., Meng, Y., Elsea, D., & Kowal, S. (2021). A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Advances in Therapy, 38(4), 1811–1831.PubMedPubMedCentralCrossRef
13.
Padula, W. V., Malaviya, S., Reid, N. M., Cohen, B. G., Chingcuanco, F., Ballreich, J., Tierce, J., & Alexander, G. C. (2021). Economic value of vaccines to address the COVID-19 pandemic: A US cost-effectiveness and budget impact analysis. Journal of Medical Economics, 24(1), 1060–1069.PubMedPubMedCentralCrossRef
14.
Whittington, M. D., Pearson, S. D., Rind, D. M., & Campbell, J. D. (2022). The cost-effectiveness of remdesivir for hospitalized patients with COVID-19. Value in Health, 25(5), 744–750.PubMedPubMedCentralCrossRef
15.
Luo, D., Wan, X., Liu, J., & Tong, T. (2018). Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Statistical Methods in Medical Research, 27(6), 1785–1805.PubMedCrossRef
16.
17.
R Development Core Team. (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing.
18.
Case, K. R., Wang, C.-P., Hosek, M. G., Lill, S. F., Howell, A. B., Taylor, B. S., Bridges, J., MacCarthy, D. J., Winkler, P., & Tsevat, J. (2022). Health-related quality of life and social determinants of health following COVID-19 infection in a predominantly Latino population. Journal of Patient-Reported Outcomes, 6, 72.PubMedPubMedCentralCrossRef
19.
Neville, T. H., Hays, R. D., Tseng, C.-H., Gonzalez, C. A., Chen, L., Hong, A., Yamamoto, M., Santoso, L., Kung, A., & Schwab, K. (2022). Survival after severe COVID-19: Long-term outcomes of patients admitted to an intensive care unit. Journal of Intensive Care Medicine, 37(8), 1019–1028.PubMedCrossRef
20.
Gamberini, L., Mazzoli, C. A., Sintonen, H., Colombo, D., Scaramuzzo, G., Allegri, D., Tonetti, T., Zani, G., Capozzi, C., & Giampalma, E. (2021). Quality of life of COVID-19 critically ill survivors after ICU discharge: 90 days follow-up. Quality of Life Research, 30(10), 2805–2817.PubMedPubMedCentralCrossRef
21.
Di Fusco, M., Sun, X., Moran, M. M., Coetzer, H., Zamparo, J. M., Puzniak, L., Alvarez, M. B., Tabak, Y. P., & Cappelleri, J. C. (2022). Impact of COVID-19 and effects of vaccination with BNT162b2 on patient-reported health-related quality of life, symptoms, and work productivity among US adult outpatients with SARS-CoV-2. Journal of Patient-Reported Outcomes, 6, 123.PubMedPubMedCentralCrossRef
22.
Sandmann, F., Tessier, E., Lacy, J., Kall, M., Van Leeuwen, E., Charlett, A., Eggo, R. M., Dabrera, G., Edmunds, W. J., & Ramsay, M. (2022). Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: Longitudinal analysis and cross-sectional comparison with controls. Clinical Infectious Diseases, 75, e962–e973.PubMedCrossRef
23.
Hodgson, C. L., Higgins, A. M., Bailey, M. J., Mather, A. M., Beach, L., Bellomo, R., Bissett, B., Boden, I. J., Bradley, S., & Burrell, A. (2021). The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: A prospective cohort study. Critical Care, 25, 382.PubMedPubMedCentralCrossRef
24.
Vlake, J. H., Van Bommel, J., Hellemons, M. E., Wils, E.-J., Bienvenu, O. J., Schut, A. F., Klijn, E., Van Bavel, M. P., Gommers, D., & Van Genderen, M. E. (2021). Psychologic distress and quality of life after ICU treatment for coronavirus disease 2019: A multicenter, observational cohort study. Critical Care Explorations, 3(8), e0497.PubMedPubMedCentralCrossRef
25.
Tran, V.-T., Riveros, C., Clepier, B., Desvarieux, M., Collet, C., Yordanov, Y., & Ravaud, P. (2022). Development and validation of the long coronavirus disease (COVID) symptom and impact tools: A set of patient-reported instruments constructed from patients’ lived experience. Clinical Infectious Diseases, 74(2), 278–287.PubMedCrossRef
26.
Dennis, A., Cuthbertson, D. J., Wootton, D., Crooks, M., Gabbay, M., Eichert, N., Mouchti, S., Pansini, M., Roca-Fernandez, A., & Thomaides-Brears, H. (2023). Multi-organ impairment and long COVID: A 1-year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine, 116(3), 97–112.PubMedPubMedCentralCrossRef
27.
Mammi, P., Ranza, E., Rampello, A., Ravanetti, D., Cavaldonati, A., Moretti, S., Gobbi, E., Rodà, F., & Brianti, R. (2023). Post–COVID-19 ongoing symptoms and health-related quality of Life: Does rehabilitation matter?: Preliminary evidence. American Journal of Physical Medicine & Rehabilitation, 102(3), 241.CrossRef
28.
Tak, C. R. (2023). The health impact of long COVID: A cross-sectional examination of health-related quality of life, disability, and health status among individuals with self-reported post-acute sequelae of SARS CoV-2 infection at various points of recovery. Journal of Patient-Reported Outcomes, 7, 31.PubMedPubMedCentralCrossRef
29.
Demoule, A., Morawiec, E., Decavele, M., Ohayon, R., Malrin, R., Galarza-Jimenez, M. A., Laveneziana, P., Morelot-Panzini, C., Similowski, T., & De Rycke, Y. (2022). Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission. Annals of Intensive Care, 12, 16.PubMedPubMedCentralCrossRef
30.
Farhanah, N., Budiman, C., Sofro, M. A. U., Riyanto, B., Hadisaputro, S., & Gasem, M. H. (2022). The persistent symptoms and decreased quality of life of COVID-19 patients (A 3-month follow-up after discharge). Open Access Macedonian Journal of Medical Sciences, 10, 1419–1425.CrossRef
31.
Hegde, S., Sreeram, S., Bhat, K. R., Satish, V., Shekar, S., & Babu, M. (2022). Evaluation of post-COVID health status using the EuroQol-5D-5L scale. Pathogens and Global Health, 116(8), 498–508.PubMedPubMedCentralCrossRef
32.
Shah, A. S., Ryu, M. H., Hague, C. J., Murphy, D. T., Johnston, J. C., Ryerson, C. J., Carlsten, C., & Wong, A. W. (2021). Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: A longitudinal, prospective cohort study. ERJ Open Research, 7(3), 00243–02021.PubMedPubMedCentralCrossRef
33.
Gamberini, L., Mazzoli, C. A., Prediletto, I., Sintonen, H., Scaramuzzo, G., Allegri, D., Colombo, D., Tonetti, T., Zani, G., & Capozzi, C. (2021). Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study. Respiratory Medicine, 189, 106665.PubMedPubMedCentralCrossRef
34.
Wen, J., Al Sayah, F., Simon, R., Lahtinen, M., Johnson, J. A., & Ohinmaa, A. (2022). Self-reported health-related quality of life of the general population in Alberta, Canada during the COVID-19 pandemic. Journal of Patient-Reported Outcomes, 6, 109.PubMedPubMedCentralCrossRef
35.
Wong, E.L.-Y., Li, J., Yuen, S., Lai, A.H.-Y., Cheung, A.W.-L., Yau, P.S.-Y., & Yeoh, E.-K. (2022). Vulnerable populations during COVID-19 response: Health-related quality of life among Chinese population and its influence due to socio-demographic factors and loneliness. Frontiers in Public Health, 10, 857033.PubMedPubMedCentralCrossRef
36.
García-de-Miguel, M., Huertas-Hoyas, E., Pérez-Corrales, J., Rodríguez-Rivas, C., García-Bravo, C., García-Bravo, S., & Camacho-Montaño, L. R. (2022). Food intake changes and their impact on quality of life in Spanish Citizens with and without COVID-19 during Lockdown. Healthcare, 10(8), 1414.PubMedPubMedCentralCrossRef
37.
Mitchell, P. M., Morton, R. L., Hiligsmann, M., Husbands, S., & Coast, J. (2022). Estimating loss in capability wellbeing in the first year of the COVID-19 pandemic: A cross-sectional study of the general adult population in the UK, Australia and the Netherlands. The European Journal of Health Economics, 24, 609–619.PubMedPubMedCentralCrossRef
38.
Poder, T. G., Dufresne, É., He, J., Talba, L., & Da Silva, R. B. (2021). Qualité de vie reliée à la santé et confinement: Analyse des effets et des facteurs de risque [Health-related quality of life and lockdown: Analysis of effects and risk factors]. International Journal of Health Preference Research, 1, 2–26.
39.
Tamson, M., Reile, R., Sokurova, D., Innos, K., Nurk, E., Laidra, K., & Vorobjov, S. (2022). Health-related quality of life and its socio-demographic and behavioural correlates during the COVID-19 pandemic in Estonia. International Journal of Environmental Research and Public Health, 19(15), 9060.PubMedPubMedCentralCrossRef
40.
Chen, J., Gong, C. L., Persson, U., & Gu, N. Y. (2023). A cross-country comparison of health-related quality of life in the United States, Sweden, and Norway during the first year of the COVID-19 pandemic. Archives of Public Health, 81(1), 58.PubMedPubMedCentralCrossRef
41.
Long, D., Haagsma, J. A., Janssen, M. F., Yfantopoulos, J. N., Lubetkin, E. I., & Bonsel, G. J. (2021). Health-related quality of life and mental well-being of healthy and diseased persons in 8 countries: Does stringency of government response against early COVID-19 matter? SSM-population health, 15, 100913.PubMedPubMedCentralCrossRef
42.
Luyten, J., Marais, C., Hens, N., De Schrijver, K., & Beutels, P. (2011). Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: A comparison of methods for hepatitis a patients. Value in Health, 14(2), 282–290.PubMedCrossRef
43.
Marra, C. A., Esdaile, J. M., Guh, D., Kopec, J. A., Brazier, J. E., Koehler, B. E., Chalmers, A., & Anis, A. H. (2004). A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Medical Care, 42, 1125–1131.PubMedCrossRef
44.
Bryan, S., & Longworth, L. (2005). Measuring health-related utility: Why the disparity between EQ-5D and SF-6D? The European Journal of Health Economics, 6, 253–260.PubMedCrossRef
45.
Bailey, H., & Kind, P. (2010). Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets. Quality of Life Research, 19(8), 1145–1154.PubMedCrossRef
46.
Matter-Walstra, K., Klingbiel, D., Szucs, T., Pestalozzi, B. C., & Schwenkglenks, M. (2014). Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? PharmacoEconomics, 32(6), 591–599.PubMedCrossRef
47.
Kohli, M., Maschio, M., Becker, D., & Weinstein, M. C. (2021). The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine, 39(7), 1157–1164.PubMedPubMedCentralCrossRef
48.
Higgins, J. P., & Thompson, S. G. (2004). Controlling the risk of spurious findings from meta-regression. Statistics in Medicine, 23(11), 1663–1682.PubMedCrossRef
Metagegevens
Titel
COVID-19-related health utility values and changes in COVID-19 patients and the general population: a scoping review
Auteurs
Zhuxin Mao
Xiao Li
Mark Jit
Philippe Beutels
Publicatiedatum
11-01-2024
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-023-03584-x

Andere artikelen Uitgave 6/2024

The quality of life impact of the COVID-19 pandemic and lockdowns for people living with multiple sclerosis (MS): evidence from the Australian MS Longitudinal Study

  • Open Access

The Hemodialysis Distress Thermometer for Caregivers (HD-DT-C): development and testing of the psychometric properties of a new tool for screening psychological distress among family caregivers of adults on hemodialysis

  • Open Access

Construct validity of the 12-item Short Form Health Survey (SF-12) version 2 and the impact of lifestyle modifications on the health-related quality of life among Indian adults with prediabetes: results from the D-CLIP trial

Association between sleep quality and quality of life in Singapore

Relative importance of selected predictors of health-related quality-of-life (HRQOL) among U.S. adults

Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV)